ArticleMicrobiology spectrum2025
Generation of nanobodies against the F protein of respiratory syncytial virus and establishment of an indirect immunofluorescence assay.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Broadly neutralizing nanobodies target a defined structural pivot site on the RSV fusion protein.EMBO molecular medicine · 2026Article
- Epidemiological and clinical characteristics of respiratory syncytial virus infection in hospitalized neonates in Suzhou.Translational pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) infection is a leading cause of acute respiratory infections and death in children and older adults. Currently, there is a lack of effective vaccines and antibody treatments on the market, and the clinical manifestations of RSV are indistinguishable from those of acute respiratory infections caused by other etiologies. Therefore, the prevention and treatment of RSV require not only effective vaccines but also simple, fast, cost-effective, and accurate detection and diagnostic methods. Given the small molecular weight, excellent antigen-binding specificity, and affinity of nanobodies, we successfully obtained a panel of nanobodies by expressing the RSV F protein, immunizing camel, and establishing a phage display library. Among them, F-E2 has been shown to bind specifically to the RSV F protein and can be used for Western blot, enzyme-linked immunosorbent assay, flow cytometry, immunohistochemistry, and immunofluorescence assays. Moreover, an RSV immunofluorescence detection method based on F-E2 has been established and proved to be highly specific, sensitive, cost-effective, and fast, with great application potential. IMPORTANCE: A respiratory syncytial virus (RSV) detection nanobody, F-E2, was successfully screened by constructing a dromedary camel immune library. F-E2 binds to RSV F with ng affinities and can be used for Western blot, enzyme-linked immunosorbent assay, flow cytometry, immunohistochemistry, and immunofluorescence assays. Importantly, a high-throughput RSV immunofluorescence detection method based on F-E2 has been established and proved to be highly specific, sensitive, cost-effective, and fast, with great application potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.